Could cabozantinib be a successful novel therapy for mCRPC?
ICON8: Outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer
Live long and PROSPER: enzalutamide for nmCRPC
ESMO 2016: Press brief on the results from the EORTC 18071 randomized double-blind trial
Emerging immunotherapies for kidney cancer